Table 2 BBN cross-validation results for each train-and-test pair and a posteriori testing results
From: Development of a clinical decision model for thyroid nodules
| Â | AUC | PV @ 50% | Cancer, At 50% Threshold | Benign, At 50% Threshold | ||||
|---|---|---|---|---|---|---|---|---|
| Â | Benign | Cancer | Benign | Cancer | Sensitivity | Specificity | Sensitivity | Specificity |
Test 1 | 71.4% | 71.5% | 60.0% | 66.7% | 66.8% | 50.0% | 60.0% | 58.3% |
Test 2 | 93.4% | 93.4% | 80.0% | 81.8% | 81.8% | 70.0% | 90.0% | 81.7% |
Test 3 | 89.2% | 88.7% | 81.3% | 85.7% | 66.8% | 85.7% | 92.9% | 55.6% |
Test 4 | 89.8% | 89.1% | 81.8% | 66.7% | 90.0% | 69.2% | 77.1% | 80.0% |
Test 5 | 92.1% | 92.2% | 77.8% | 91.7% | 92.4% | 87.5% | 87.6% | 77.0% |
Test 6 | 99.8% | 99.8% | 100.0% | 100.0% | 100.0% | 91.6% | 100.0% | 77.8% |
Test 7 | 76.0% | 76.0% | 80.0% | 80.0% | 90.0% | 80.0% | 80.0% | 70.0% |
Test 8 | 90.6% | 90.5% | 78.6% | 85.7% | 66.8% | 83.3% | 100.0% | 33.3% |
Test 9 | 89.8% | 90.5% | 80.0% | 81.8% | 81.8% | 70.0% | 90.0% | 72.7% |
Test 10 | 88.2% | 88.2% | 70.0% | 91.7% | 85.6% | 87.5% | 87.6% | 28.6% |
Mean | 88.0% | 88.0% | 78.9% | 83.2% | 82.2% | 77.5% | 86.5% | 63.5% |
Internal | 88.6% | 89.0% | 81.5% | 82.6% | 81.8% | 81.3% | 82.4% | 81.0% |